Levomilnacipran and vortioxetine: Review of new pharmacotherapies for major depressive disorder

Table 2 Pharmacokinetic parameters for levomilnacipran and vortioxetine[3,20,21,24]

	Levomilnacipran	Vortioxetine
Bioavailability	92%	75% ± 9%
Tmax	6-8 h	3-16 h
Volume of distribution	387-473 L	2400 L
Metabolism	Oxidation (primarily through CYP3A4), glucuronidation	Oxidation (primarily through CYP2D6), glucuronidation
Elimination	58% urine	50% urine, 26% feces
Clearance	21-29 L/h	38 L/h
Half-life	12 h	57-66 h
Protein binding	22%	98%-99%

CYP: Cytochrome P450; T_max: Time to maximum plasma concentration.